Melcior Riera

Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

Estebán Martínez, Juan A. Arnaiz, Daniel Podzamczer et al. · New England Journal of Medicine · 2003 · 293 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero et al. · The Lancet Infectious Diseases · 2015 · 131 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy

Ángeles Jaén, Anna Esteve, Josep M. Miró et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2008 · 67 citations

Public Health, Infectious Diseases, Clinical Epidemiology +15

Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection

Arkaitz Imaz, S Villar del Saz, Ma Angels Ribas et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 56 citations

Medicine, Pharmacology, Pharmacotherapy +17

Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults

María Luz Pintos Peñaranda, Antoni Payeras, Ana Cambra Conejero et al. · AIDS · 2010 · 41 citations

Veterinary Medicine, Immunology, Infectious Diseases +14